Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario, Canada L3R 5H6
August 10, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Edesa Biotech, Inc. Registration Statement on Form S-3 (File No. 333-266604) Filed on August 5, 2022 |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Edesa Biotech, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on August 12, 2022, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.
| Very truly yours, | ||
| EDESA BIOTECH, INC. | ||
| By: | /s/ Kathi Niffenegger | |
| Name: Kathi Niffenegger | ||
| Title: Chief Financial Officer | ||
